Economic Evaluation of Extended-Release Amphetamine (Dyanavel XR) Among Individuals with Attention-Deficit/Hyperactivity Disorder From a United States Societal Perspective

ClinicoEconomics and Outcomes Research · Published 2025-12-01 · DOI 10.2147/ceor.s575004

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.2147/ceor.s575004

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• Economic Burden of Overall and Advanced Light Chain Amyloidosis: Results from a Claims Linked Electronic Health Record Database Analysis · ClinicoEconomics and Outcomes Research · 2026 · Same journal
• Retrospective Study of Real-World Treatment Patterns of Subcutaneous Semaglutide Use Among Patients with Metabolic Dysfunction-Associated Steatohepatitis in the United States · ClinicoEconomics and Outcomes Research · 2025 · Same journal
• Cost-Effectiveness Analysis and Priority Setting in the Transition from Iron-Folic Acid (IFA) to Multiple Micronutrient Supplementation (MMS) for Pregnant Women in Indonesia · ClinicoEconomics and Outcomes Research · 2025 · Same journal
• Characteristics and Utilization Patterns of Medicare Beneficiaries Initiating Long-Acting Injectable Antipsychotic Medications · ClinicoEconomics and Outcomes Research · 2026 · Same journal
• Cost-Utility Analysis of Renal Replacement Therapy Modalities in the Management of Severe Acute Kidney Injury in US Critically Ill Patients · ClinicoEconomics and Outcomes Research · 2025 · Same journal
• Retrospective Database Analysis of the Clinical and Economic Outcomes Associated with Disruptive Surgical Bleeding · ClinicoEconomics and Outcomes Research · 2025 · Same journal
• Socio-Economic Impacts of Childhood Sickle Cell Disease on Households in Lubumbashi: An Exploratory Mixed-Methods Study · ClinicoEconomics and Outcomes Research · 2026 · Same journal
• Early Health Technology Assessment (HTA) of Olpasiran and Pelacarsen for Secondary Prevention of Coronary Heart Disease (CHD) · ClinicoEconomics and Outcomes Research · 2026 · Same journal
• Analysis of Cost-Effectiveness of Biologic Therapies in Axial Spondyloarthritis Based on Real-World Data · ClinicoEconomics and Outcomes Research · 2025 · Same journal
• Effect of Drug Cost-Exemption Policy on Treatment Outcomes in Multidrug-Resistant Tuberculosis Patients in Guangxi Zhuang Autonomous Region, China: A Nested Case–Control Study · ClinicoEconomics and Outcomes Research · 2026 · Same journal